peptic%20ulcer%20disease
PEPTIC ULCER DISEASE
Peptic ulcer disease is the presence of ulceration in the stomach and proximal duodenum commonly and in the lower esophagus, distal duodenum or jejunum infrequently. It is characterized by mucosal damage secondary to pepsin and gastric acid secretion.
It is the principal cause of upper gastrointestinal hemorrhage.
Appropriate therapy depends on the cause of peptic ulcer disease.

Introduction

  • Peptic ulcer disease (PUD) is characterized by mucosal damage secondary to pepsin and gastric acid secretion
  • It is the principal cause of upper gastrointestinal (UGI) hemorrhage
  • Most commonly occurs in the stomach and proximal duodenum; infrequently, in the lower esophagus, distal duodenum or jejunum
  • Giant ulcer with size of 3 cm is an atypical type of PUD that is now rarely encountered
  • Dyspepsia is a nonspecific term indicating discomfort in the upper abdomen
  • Refractory PUD is considered in patents with ulcer that failed to heal after 8-12 weeks of therapy

Signs and Symptoms

Clinical Features
  • Epigastric pain is the most common symptom of PUD but occurs only in minority of patients
    • Pain of duodenal ulcer usually occurs 2-3 hours after a meal, improves with food or antacid, and sometimes awakens patient at night
    • Pain of gastric ulcer is more commonly worsened by food intake and occurs shortly after meals
      • May be associated with weight loss due to fear of food intake
  • Other symptoms include indigestion, vomiting, loss of appetite, inability to tolerate fatty foods, heartburn
    • Nausea and vomiting are commonly experienced by patients with prepyloric or pyloric channel ulcers

Alarm Symptoms

  • Hematemesis, melena, or anemia may suggest bleeding
  • Vomiting and early satiety may be due to obstruction
  • Anorexia or weight loss may suggest cancer
  • Upper abdominal pain radiating to the back that persists may be due to penetration
  • Spreading upper abdominal pain that is severe may suggest perforation

Risk Factors

Risk Factors
  • In 70% of cases, 25- to 64-year old patients are affected
  • 48% and 50% of cases are secondary to Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) respectively
    • Some evidence states that H pylori infection may be food or water borne and may spread from person to person
    • In patients with a bleeding ulcer, it is recommended to test for and treat H pylori
    • NSAIDs inhibit the formation of prostaglandins and their protective effect on the gastric mucosa (ie stimulates mucus and bicarbonate secretion, epithelial cell proliferation, and increase of mucosal blood flow)
      • Patients who are on long-term NSAIDs have an annual risk of life-threatening ulcer-related complication of 1-4%
    • H pylori plus NSAID use increases the risk and intensity of NSAID-related mucosal damage
  • Other causes may include use of steroids, bisphosphonates, potassium chloride or chemotherapeutic agents, presence of acid-hypersecretory states (eg Zollinger-Ellison syndrome), cancer or stress [eg multiorgan failure, ventilator support, extensive burns (Curling’s ulcer) or head injury (Cushing’s ulcer)], lifestyle factors, genetic factors
  • In patients with NSAID-related GI complications, additional contributing factors include history of complicated GI event, age, concomitant use of anticoagulants, corticosteroids, other NSAIDs including low-dose Aspirin, high-dose therapy, chronic debilitating disorders
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
6 days ago
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
4 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.